MedPath

GILEAD SCIENCES SL

🇺🇸United States
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
$95.8B
Website
http://www.gilead.com/about/worldwide-operations/europe/spain
Clinical Trials
Related News

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Phase 2
Completed
Conditions
HCV Infection
Interventions
Drug: placebo
First Posted Date
2008-08-29
Last Posted Date
2013-11-05
Lead Sponsor
Gilead Sciences
Target Recruit Count
252
Registration Number
NCT00743795

Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine

Phase 2
Completed
Conditions
HIV-1 Infection
Interventions
First Posted Date
2008-08-28
Last Posted Date
2018-04-26
Lead Sponsor
Gilead Sciences
Target Recruit Count
50
Registration Number
NCT00743340
Locations
🇿🇦

Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa

🇿🇦

Themba Lethu Clinic, Helen Joseph Hospital, Westdene, Johannesburg, South Africa

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Phase 2
Completed
Conditions
Nonalcoholic Steatohepatitis
Interventions
Drug: GS-9450 Placebo
First Posted Date
2008-08-25
Last Posted Date
2014-02-04
Lead Sponsor
Gilead Sciences
Target Recruit Count
124
Registration Number
NCT00740610

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Phase 3
Completed
Conditions
Hepatitis B
Interventions
Drug: FTC/TDF
Drug: FTC/TDF Placebo
Drug: TDF Placebo
First Posted Date
2008-08-19
Last Posted Date
2016-03-11
Lead Sponsor
Gilead Sciences
Target Recruit Count
280
Registration Number
NCT00737568

A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection

Phase 4
Completed
Conditions
Chronic Hepatitis B
Interventions
First Posted Date
2008-08-15
Last Posted Date
2011-12-05
Lead Sponsor
Gilead Sciences
Target Recruit Count
90
Registration Number
NCT00736190

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

Phase 3
Completed
Conditions
Hepatitis B Virus (HBV)
Interventions
Drug: Placebo
First Posted Date
2008-08-14
Last Posted Date
2016-09-01
Lead Sponsor
Gilead Sciences
Target Recruit Count
106
Registration Number
NCT00734162
Locations
🇺🇸

Riley Hospital for Children, Indianapolis, Indiana, United States

🇫🇷

Hopital Femmes Meres Enfants, Bron Cedex, France

🇪🇸

Hospital Universitario De Getafe, Madrid, Spain

and more 18 locations

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

Phase 2
Completed
Conditions
HCV Infection
Interventions
Drug: GS-9450 Placebo
First Posted Date
2008-07-31
Last Posted Date
2014-06-19
Lead Sponsor
Gilead Sciences
Target Recruit Count
33
Registration Number
NCT00725803

Safety and Efficacy Study of Switching From Epzicom to Truvada

First Posted Date
2008-07-29
Last Posted Date
2012-05-28
Lead Sponsor
Gilead Sciences
Target Recruit Count
312
Registration Number
NCT00724711
Locations
🇺🇸

Peter J. Ruane, MD, Inc., Los Angeles, California, United States

🇺🇸

Anthony M Mills, MD, Los Angeles, California, United States

🇺🇸

Orange Coast Medical Group, Newport Beach, California, United States

and more 77 locations

Safety Study of Tecadenoson to Treat Atrial Fibrillation

Phase 2
Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2008-07-11
Last Posted Date
2014-03-11
Lead Sponsor
Gilead Sciences
Target Recruit Count
21
Registration Number
NCT00713401
Locations
🇺🇸

CV Therapeutics, Inc., Palo Alto, California, United States

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

Phase 3
Completed
Conditions
Cystic Fibrosis
Lung Infection
Pseudomonas Aeruginosa
Interventions
Drug: Placebo three times daily (TID)
Drug: AZLI 75 mg three times daily (TID)
First Posted Date
2008-07-09
Last Posted Date
2010-12-20
Lead Sponsor
Gilead Sciences
Target Recruit Count
160
Registration Number
NCT00712166
Locations
🇺🇸

Children's Memorial Hospital, Chicago, Illinois, United States

🇺🇸

Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States

🇺🇸

Drexel University College of Medicine, Pulmonary Associates, Philadelphia, Pennsylvania, United States

and more 36 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy